2026 NPPES data Neurology Physician NPI 1467891671 M.D.
Verify on CMS →

RAYZA GARCIA PAREDES, M.D.

Neurology Physician in CAGUAS, Puerto Rico. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
253
Medicare Part D claims · 58 beneficiaries · Neurology Physician avg: 1K
Generic prescribing
94%
generic claims · 6% brand-name · higher generic rates reduce patient out-of-pocket costs
Industry payments
$53.09
3 payments · CMS Open Payments (Sunshine Act)

What the federal data shows

RAYZA GARCIA PAREDES, M.D. filed 253 Medicare Part D claims in 2023 as a Neurology Physician in CAGUAS, Puerto Rico, prescribing 94% generic.

253
Part D claims, 2023
94%
generic prescribing
$53.09
industry payments (Sunshine Act)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

RAYZA GARCIA PAREDES, M.D.'s Medicare Part D volume vs every U.S. prescriber

Total Medicare Part D claims, 2023 — across all CMS prescribers nationally

253 49th percentile higher than 49% of 1,370,886 prescribers

0–200: 670,926 prescribers (49%). Below this entry. 200–400: 182,923 prescribers (13%). This entry sits in this band. 400–600: 90,619 prescribers (7%). Above this entry. 600–800: 56,224 prescribers (4%). Above this entry. 800–1,000: 40,919 prescribers (3%). Above this entry. 1,000–1,200: 31,827 prescribers (2%). Above this entry. 1,200–1,400: 26,224 prescribers (2%). Above this entry. 1,400–1,600: 21,710 prescribers (2%). Above this entry. 1,600–1,800: 19,072 prescribers (1%). Above this entry. 1,800–2,000: 16,451 prescribers (1%). Above this entry. 2,000–2,200: 213,991 prescribers (16%). Above this entry. This provider 0 2K+ every Part D prescriber (claims/yr), bucketed by value

Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Medicare Part D Prescriber Public Use File · 2023

Board-eligible specialty (heuristic — not verified)

RAYZA GARCIA PAREDES, M.D. practices in an ABMS-board-eligible specialty but we don't have enough CMS-participation signals to confirm active board-certified status. Consult CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about RAYZA GARCIA PAREDES, M.D.?

Quality data not reported

NPI registry status

Active

Issued 06/20/2013

NPI 1467891671

Primary specialty

Neurology Physician

Mid-sized

19,866 US NPIs in this specialty

Medicare Part D claims

253 81% vs specialty avg

2023 prescription claims

Specialty avg: 1,309

Specialty distribution in Puerto Rico

How Neurology Physician compares to other specialties among Puerto Rico providers

Puerto Rico providers

Neurology Physician share within Puerto Rico

1. Neurology Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Neurology Physician share within Puerto Rico

Specialty board-certification context

Estimated specialty board-certified rate — Neurology Physician (ABMS / AOA reference)

Quality data not reported
Est. board-certified rate
78%
Neurology Physician ABMS/AOA estimate

Est. board-certified rate (Neurology Physician) — ABMS / AOA estimate

0%100%78%
Est. board-certified rate (Neurology Physician) — ABMS / AOA estimate

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

RAYZA GARCIA PAREDES, M.D. appears in the CMS NPPES registry as a Neurology Physician provider holding M.D. credentials at GATSBY PLAZA SUITE 318, CAGUAS, PR, 00725, with a listed phone of (787) 234-2267. NPI 1467891671 was issued on 06/20/2013. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what GARCIA PAREDES most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 253 prescription claims written by this provider, covering 58 Medicare beneficiaries and totaling roughly $13K in drug spend, split 6% brand-name and 94% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.

Neurology Physician is a mid-sized specialty nationwide, with 19,866 enrolled providers across 54 states and an average of 1,309 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

GATSBY PLAZA SUITE 318
CAGUAS, PR 00725

Provider Details

NPI 1467891671
Specialty Neurology Physician
Credentials M.D.
Gender Female
NPI Issued 06/20/2013

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for RAYZA GARCIA PAREDES, M.D.. Source: openpaymentsdata.cms.gov.

Total received

$53

Largest payer

PBG PUERTO RICO LLC

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

Brand vs generic prescribing mix · Generic-heavy

RAYZA GARCIA PAREDES, M.D. — brand share 6.0%
Specialty average (est.)

6% brand-name claims vs 94% generic, on 253 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

253
Total Claims
$13K
Total Drug Cost
58
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
298
Total Day Supply
8,500
Brand vs Generic
6% brand / 94% generic
Brand Drug Cost
$8K
Generic Drug Cost
$5K

Patient Demographics

Average Patient Age
73.8 years
Avg HCC Risk Score
1.70
Gender Split
66% female / 34% male

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What RAYZA GARCIA PAREDES, M.D. prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Donepezil Hcl
46
Sertraline Hcl
30
Rivastigmine
Rivastigmine Tartrate
23
Primidone
17
Carbidopa-Levodopa
Carbidopa/Levodopa
16
Memantine Hcl
16
Naproxen Sodium
14
Prednisone
14
Emgality Pen
Galcanezumab-Gnlm
12
Pyridostigmine Bromide
12

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Neurology Physician Overview

How RAYZA GARCIA PAREDES, M.D. fits within the Neurology Physician landscape nationally.

19,866
Neurology Physician Providers in US
54
States with Neurology Physician
1,309
Avg Claims per Provider

RAYZA GARCIA PAREDES, M.D.'s 253 claims are below the specialty average of 1,309.

Nearby Neurology Physician Providers in Puerto Rico

Other clinicians with the same primary specialty enrolled in Puerto Rico, drawn from the same CMS NPPES roster as GARCIA PAREDES.

Compare Neurology Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is RAYZA GARCIA PAREDES, M.D.'s specialty?
RAYZA GARCIA PAREDES, M.D. specializes in Neurology Physician and practices in CAGUAS, Puerto Rico. Credentials: M.D..
How much does RAYZA GARCIA PAREDES, M.D. prescribe under Medicare Part D?
In 2023, RAYZA GARCIA PAREDES, M.D. wrote 253 Medicare Part D claims totaling $13K in drug costs for 58 beneficiaries.
Where is RAYZA GARCIA PAREDES, M.D. located?
RAYZA GARCIA PAREDES, M.D. is located at GATSBY PLAZA SUITE 318, CAGUAS, PR, 00725. Phone: (787) 234-2267.
What is RAYZA GARCIA PAREDES, M.D.'s NPI number?
RAYZA GARCIA PAREDES, M.D.'s National Provider Identifier (NPI) is 1467891671, issued on 06/20/2013.
Does RAYZA GARCIA PAREDES, M.D. prescribe more brand-name or generic drugs?
RAYZA GARCIA PAREDES, M.D.'s prescribing is 6% brand-name and 94% generic drugs by claim count, with $8K in brand drug costs.
How many Neurology Physician providers are there in the US?
There are 19,866 Neurology Physician providers across 54 states in the US. The average Neurology Physician provider writes 1,309 Medicare Part D claims per year.
What drugs does RAYZA GARCIA PAREDES, M.D. prescribe most often?
Based on 2023 Medicare Part D data, RAYZA GARCIA PAREDES, M.D.'s most frequently prescribed drugs include Donepezil Hcl, Sertraline Hcl, Rivastigmine. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does RAYZA GARCIA PAREDES, M.D. accept Medicare?
RAYZA GARCIA PAREDES, M.D. appears in CMS Medicare data with 253 Part D claims and 58 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify RAYZA GARCIA PAREDES, M.D.'s credentials?
RAYZA GARCIA PAREDES, M.D.'s NPI is 1467891671 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology